Group 1 - The Chengdu Qingyang District Health Bureau announced the procurement results for automatic external defibrillators (AEDs) for public places in 2025, with Sichuan Jiuzhoutong Medical Equipment Supply Chain Management Co., Ltd. winning the bid [1][2] - The total bid amount for the procurement project is 3,686,320.00 yuan, with a total score of 99.80 in the evaluation [3][2] - The company will supply 176 sets of Mindray's AEDs at a unit price of 16,980.00 yuan and 176 sets of Meisen's intelligent AED cases at a unit price of 3,965.00 yuan [3][1] Group 2 - Sichuan Jiuzhoutong Medical Equipment Supply Chain Management Co., Ltd. was established in 2023 with a registered capital of 60 million yuan and is a subsidiary of Jiuzhoutong Pharmaceutical Group Co., Ltd. [4] - The actual controller of the company holds a voting power of 51% and a total shareholding ratio of 9.7482% [5]

二、优先股股息派发方案 根据公司披露的《九州通向特定对象发行优先股募集说明书》约定，计息起 证券代码：600998 证券简称：九州通 公告编号：临 2025-058 九州通医药集团股份有限公司 优先股 2025 年股息派发实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、优先股股息派发审议情况 九州通医药集团股份有限公司（以下简称"公司"）2022 年第二次临时股东 大会审议通过了《关于公司非公开发行优先股方案的议案》，授权董事会在股东 会审议通过的框架和原则下，依照发行文件的约定，宣派和支付全部优先股股息。 2025 年 6 月 17 日，公司召开第六届董事会第十五次会议，审议通过了《关于公 司优先股股息派发方案的议案》，同意按照 5.00%的票面股息率（票面面值为 100 元/股），向优先股股东派发股息每股 5.00 元（含税）（详见公司公告：临 2025-047）。 全体优先股股东的股息由公司自行发放。 四、有关咨询方式 1、联系部门：公司董事会秘书处 1 优先股代码：360047 优先股简称： ...

Canalys（现并入Omdia）研究经理Himani Mukka 表示："在中国消费者补贴政策的支持以及全球商用招标项目的推动下，全球平板市场在第二季度继续展 现出强劲的增长势头。市场还受益于一波新品发布热潮，尤其是在游戏平板领域。随着消费者对游戏场景的兴趣日益增长，游戏平板已成为一个细分增 长品类，尤其在亚洲地区表现突出。值得关注的新品包括小米的Redmi K Pad（8.8英寸）和vivo的Pad5，联想的Legion Tab季度出货量更是翻倍增长。厂 商们也在将平板作为其互联生态战略的关键组成部分。荣耀在第一季度率先发布'Alpha'计划，小米则于5月推出'人车家全生态'战略，旨在无缝整合智能 手机、平板、智能家居设备，甚至新能源汽车。新发布的小米Pad 7 Ultra正是该生态中的核心控制枢纽。" | 全球平板电脑出货量 (市场份额和年增长率) | | | | | | | --- | --- | --- | --- | --- | --- | | Canalys PC 分析统计数据: 2025 年第二季度 | | | | | | | 2025 年 | | 2025 年 | 2024 年 | 2024 ...

| 序号 | 股东名称 | 持股比例 ÷ | 认缴出资额 # | 认缴出资日期 ៖ 首次持股日期 ៖ | | --- | --- | --- | --- | --- | | | 九州通医疗器械集团有限公司 | 51.00% | 1020万元 | 2025-07-24 | | | 大股东 | | | | | | + 九州通医药集团股份有限公司 | 81.4229% | 31500.5192万元 | 2019-12-31 | 企查查APP显示，近日，九州通芯康（上海）医疗器械有限公司成立，法定代表人为王岭，注册资本为2000万元，经营范围包含：第三类医疗器械经营；药 品批发；消毒剂销售（不含危险化学品）；日用品销售；化妆品批发等。企查查股权穿透显示，该公司由九州通（600998）旗下九州通医疗器械集团有限公 司等共同持股。 | CAM W W W W W W W W ST ST ST ST ST ST ST ST ST LE FOR ST LE FOR ST LE FOR STORE FOR STATE FOR × 查一下 个小中心 0 0 九州通芯康（上海）医疗器械有限公司 ・ 応用 ▼ 应经知旺思言公园分 。 ...

Company Overview - Xiamen Jiuzhoutong Medical Supply Chain Management Co., Ltd. was recently established with a registered capital of 5 million RMB [1][2] - The legal representative of the company is Gao Qianjun, and it is wholly owned by Fujian Jiuzhoutong Medical Supply Chain Management Co., Ltd. [1][2] Business Scope - The company’s business scope includes supply chain management services, sales of Class I and Class II medical devices, chemical products sales (excluding licensed chemical products), cosmetics wholesale and retail, daily necessities sales, health consulting services (excluding diagnostic services), and enterprise management [1] - Additional services include machinery equipment leasing, social and economic consulting, information consulting (excluding licensed information consulting), translation services, low-temperature warehousing (excluding hazardous chemicals), general cargo warehousing (excluding hazardous chemicals), software sales and development, technical services, and computer hardware and software sales [1] - The company is also involved in the sale and repair of specialized equipment, electrical equipment, and teaching models, as well as information system integration services and construction decoration materials sales [1] Licensing and Regulatory Compliance - The company is authorized to operate in several licensed areas, including the operation of Class III medical devices, leasing of Class III medical equipment, sales of disinfecting devices, and medical device internet information services [1] - All operations are subject to approval by relevant authorities, and specific business activities will be conducted in accordance with the approved documents or permits [1]

行业主要上市公司：国药控股(01099.HK);上海医药(601607.SH);华润医药(03320.HK);九州通(600998.SH);南京医药(600713.SH);华东医药(000963.SZ);英特集团(000411.SZ) 本文核心数据：战略集群;市场排名;波特五力模型; 中国医药流通市场竞争梯队 目前我国医药流通行业企业可以划分为三个竞争梯队。处于第一梯队的是全国性批发巨头，中国医药、上海医药、华润医药及九州通，收入在千亿以上水平;处于第二梯队的是广州医药、南京医 中国医药流通行业零售药店排名 根据榜单，大参林夺得龙头宝座，排名第一，国大药房位居第二，益丰排名第三;老百姓、一心堂位列第4名和第5名。值得注意的是，今年榜单前5名顺序，与2022-2023年年变化较大。另外， | 排名 | | 品牌名称 | | --- | --- | --- | | 1 | 大参林大药房 | | | 2 | 国药大药房 | | | ૮૮ | 益丰大药房 | | | 4 | 老百姓大药房 | | | 5 | 一心堂大药房 | | | 6 | 海王星辰大药房 | | | 7 | 全亿大药房 | | | 8 | 漱玉平民 ...

Core Insights - The Chinese pharmaceutical distribution market is segmented into three competitive tiers, with major players like China National Pharmaceutical, Shanghai Pharmaceuticals, and China Resources Pharmaceutical leading the first tier with revenues exceeding 100 billion [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoda Pharmacy and Yifeng Pharmacy, indicating significant changes in the rankings from 2022-2023 [3][4] - In the e-commerce sector, Fangzhou Jianke leads the online pharmacy rankings, emphasizing the shift towards technology-driven healthcare solutions [5] Competitive Landscape - The pharmaceutical distribution industry is characterized by intense competition, with numerous participants including wholesale, retail, and brand operation companies, as well as e-commerce platforms entering the market [7] - The five forces analysis indicates a high threat from potential entrants and moderate bargaining power from downstream medical institutions and patients [7] - The strategic cluster analysis reveals that leading companies like China Resources Pharmaceutical and Shanghai Pharmaceuticals are positioned as market leaders due to their extensive experience and comprehensive business layouts [5][6] Retail Pharmacy Rankings - The top five retail pharmacies are Dazhenlin, Guoda Pharmacy, Yifeng Pharmacy, Laobaiyi, and Yixintang, reflecting a dynamic market with significant shifts in rankings [3][4] - Other notable pharmacies in the top 25 include Henan Zhang Zhongjing Pharmacy and Shandong Yanjitang, showcasing a diverse competitive landscape [3] E-commerce Pharmacy Rankings - Fangzhou Jianke leads the online pharmacy sector, followed by 1Yao.com and JD Health, highlighting the growing importance of digital platforms in the pharmaceutical distribution market [5] - The focus on technology and innovation is evident as companies aim to connect patients with medical services more effectively [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券时报记者 赵梦桥 公募REITs生态的健康发展离不开发行人、监管方、中介机构、投资者等多方主体的协同发力。在证券时报社主办 的"变革与突围·中国基金业高质量发展系列沙龙"之"掘金公募REITs大时代·生态共建与价值共生"的圆桌论坛环 节，华夏基金、东吴基金、国寿资产、新华资产以及九州通等多家机构和上市公司的嘉宾，阐释了各自视角里"多 层次REITs生态体系"急需补强的环节，并为推动各方实现真正的"价值共生"建言献策。 提高流动性为第一要务 面对当前公募REITs市场存在的资产供给不足、估值分歧、流动性待提升等瓶颈问题，与会嘉宾从生态共建角度提 出了多项建议。 制度完善 或可借鉴股票市场 除了规模困局待解以外，制度的完善也是REITs业务走向成熟的必经之路。 华夏基金基础设施与不动产业务部行政负责人莫一帆指出，Pre-REITs、私募REITs承担了优质资产储备和孵化的功 能，但目前从Pre-REITs/私募REITs到公募REITs的退出路径尚不清晰。在原始权益人认定、净回收资金投资等方面 细节，有待进一步明确和优化。 莫一帆强调，相关各方可推动政策优化完 ...

Core Insights - The private economy in Wuhan has surpassed 1 trillion yuan, reaching 1.02 trillion yuan in 2024, marking a significant milestone for the region [1] - The top three private enterprises in Hubei, including Jiuzhoutong Pharmaceutical Group and Hengxin Automobile Group, are located near Longyang Lake, contributing to a high concentration of private enterprises in the area [1][2] - Over the past five years, the Longyang Lake area has developed into a 100 billion yuan private economic belt, with Jiuzhoutong's revenue exceeding 150 billion yuan and Hengxin's surpassing 80 billion yuan in 2024 [1][5] Company and Industry Summaries - Jiuzhoutong has grown from 41.1 billion yuan in revenue in 2014 to 151.81 billion yuan in 2024, demonstrating significant growth as a "chain leader" in the health sector [4][11] - The Jiuzhoutong Health City has achieved over 95% occupancy within two years, housing 148 enterprises across various sectors, including health, finance, and software development [4] - Hengxin Automobile Group has established itself as a leading player in the automotive sector, contributing to a nearly 100 billion yuan automotive sales cluster in the region [5][11] - The Longyang Lake area has attracted 1.1 million enterprises, with over 99% being private, reflecting an 88% increase since 2020 [2] - The innovation ecosystem in the Longyang Lake area has fostered the growth of various industries, including health, automotive, technology, and cultural tourism, creating a closed-loop economy [10][12] - Jiuzhoutong's digital transformation has led to 1.25159 billion yuan in revenue from digital pharmaceutical distribution and supply chain services, highlighting the importance of innovation in driving growth [11] - The establishment of the AI Medical Innovation Unit in collaboration with Han Yang Technology Innovation Research Institute has resulted in a 90% increase in revenue for companies like Xingxue Data [10][11]

安湃光电建成全球首条自主8英寸薄膜铌酸锂流片产线，抢占下一代光通信黄金赛道；"独角兽"企业芯擎科技智能座舱芯片串起武汉智 能网联汽车产业链；禾元生物、衷华脑机等多家民企逐浪在未来产业赛道。 我市转型发展还处在爬坡过坎的关键阶段，民营企业正以硬核实力扛起担当，坚定发展信心，为加快推动"三个优势转化"、重塑新时 代武汉之"重"提供坚实支撑。 今年上半年，以民营企业为重要力量的全市高技术制造业增加值增长15.7%，民营企业贡献全市近五成税收。武汉民企正深扎城市肌 理的根系，以经年生长的韧劲，与城市共成长。 九州通每年在数字化和基层医疗服务体系建设方面的投入将近3亿元。刘长云说："企业家要坚持内涵式增长，追求高质量发展。" 在武汉民营经济高质量发展的浪潮中，众多企业以咬定青山不放松的定力深耕主业，以万丈高楼平地起的韧劲做强实业。 陈吉红将数控机床比喻为"老骨头熬汤"，从2009年到2024年，他创立的华中数控研发费用增长了24倍。最近，企业带着华中10型智能 数控系统登陆工信部"工业母机+"对接活动；冯裕才45年来把数据库做到极致，他说，企业不做"万金油"。2025年一季度，冯裕才创立的达 梦数据库营收和归母净利润同 ...